Opportunities Preloader

Please Wait.....

Report

Johnson & Johnson (JNJ:NYSE) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360? Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI?s, and Recent Trends

Company Report I 2025-02-27 I 111 Pages I Quaintel Research

Report Summary

Johnson & Johnson (JNJ:NYSE) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPIs, and Recent Trends Report is a comprehensive and easily accessible overview of Johnson & Johnson's business operations. It provides a detailed analysis of the company's financial and strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.

The report begins with in-depth information about Johnson & Johnson, including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.

Next, the report assesses Johnson & Johnson's strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. The PESTLE analysis evaluates the external factors impacting the company's operations and market environment. Additionally, By integrating these strategic analyses, the report offers a comprehensive understanding of Johnson & Johnson's overall strategic standing and supports informed decision-making and strategic planning.

The report also covers Johnson & Johnson's financial analysis basis of latest income statement, balance sheet, and cash flow statement. Key financial ratios related to profitability, asset turnover, credit, market, and long-term solvency are outlined, providing guidance for investment decisions. Furthermore, the report compares Johnson & Johnson's financial parameters with those of its competitors, offering a unique analysis of the competitive landscape. This information helps manage the business environment and improve sales activities by gaining insight into competitors' operations.

Finally, the report includes recent news and deal activities undertaken by Johnson & Johnson, enhancing awareness of the company's business trends, growth perspectives, and more.

Key Highlights

Johnson and Johnson operates as a healthcare focused company that researches, develops, manufactures, and sells various products in the healthcare field worldwide. Johnson and Johnson operates in three main business segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers over-the-counter medicines and personal care products. The Pharmaceutical segment provides prescription drugs. The Medical Devices segment offers surgical equipment, orthopedic products, cardiovascular devices, and vision care products. Johnson and Johnson offers a broad range of health care products across three business segments: Consumer Health, Pharmaceutical, and Medical Devices. Some of the key products and services include over-the-counter medicines like Tylenol, Band-Aid, Benadryl, and Zyrtec; prescription drugs for immunology, infectious diseases, neuroscience, oncology, and cardiovascular diseases; medical devices for orthopedics, surgery, cardiovascular disease, and vision care including joint replacements, surgical tools and equipment, contact lenses, and laser refractive surgical technologies. Founded in 1887, the company is headquartered in New Brunswick, New Jersey, United States.

Johnson and Johnson in the News:-

- 14-Feb-2025 - Johnson and Johnson to Resume U.S. VARIPULSE Cases
- 13-Feb-2025 - New nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody diseases
- 13-Feb-2025 - Johnson and Johnson Statement on Phase 3 E.mbrace Study
- 03-Feb-2025 - CHMP recommends subcutaneous RYBREVANT (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer
- 21-Jan-2025 - SPRAVATO (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression


Scope

Tactical Analysis:- Various strategic frameworks to gain insights into a company's competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
Business Strategy:- Contributes to shaping the company's overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
Financial Position:- Provide valuable information on the financial performance and investor sentiment surrounding the company. Indicating the level of confidence and expectations in the company's future prospects. These components collectively contribute to understanding the financial health and market perception of the company.
Company Fundamentals:- These fundamentals offer valuable insights into the company's history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
Competitive Landscape:- An identification of the company's main competitors, providing insights into the competitive landscape it operates in.

Reasons to Buy

Comprehensive Understanding of the Johnson & Johnson's internal and external factors through SWOT analysis, PESTLE analysis, Financial Analysis, and Competitors Benchmarking.
Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
Financial Performance Evaluation provides crucial insights into key financial ratios and trends, supporting better financial decision-making and resource allocation.
Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.

Additionally, available deep-dive analysis on the company Johnson & Johnson:
Johnson & Johnson Porter's Five Forces Analysis
Johnson & Johnson VRIO Analysis
Johnson & Johnson BCG Analysis
Johnson & Johnson Segmentation, Targeting and Positioning (STP) Analysis
Johnson & Johnson Ansoff Matrix Analysis

Table of Contents
COMPANY EXECUTIVE SUMMARY 1
Table of Contents 2
Tables 6
Charts 7
Johnson & Johnson - Key Company Facts 8
Johnson & Johnson - Company Description 9
Johnson & Johnson - Top Executives 10
Johnson & Johnson- Top Executives Biographies 11
Johnson & Johnson- Head Office & Locations 15
Head Office - Country 15
Key Subsidiaries 16
Key Joint Ventures 17
Johnson & Johnson - Products and Services 18
Products 18
Johnson & Johnson - Historic Events 20
Johnson & Johnson - Company's Mission and Vision 22
Mission 22
Vision 22
Johnson & Johnson - Corporate Strategy 23
Johnson & Johnson - Business Description 25
Innovative Medicine 26
MedTech 26
Johnson & Johnson - ESG Spotlight 28
Environment 28
Social 28
Corporate Governance 29
Johnson & Johnson - SWOT Analysis 30
Overview 30
Strengths 32
Weaknesses 36
Opportunities 38
Threats 40
Johnson & Johnson - PESTLE Analysis 43
Overview 43
Political Factors 45
Economic Factors 47
Social Factors 49
Technological Factors 51
Legal Factors 53
Environmental Factors 55
Johnson & Johnson - Financial Deep Dive 56
Share Price Trend - Feb-2024 to Feb-2025 (Average Share Closing Price) 56
Profit and Loss Statement 58
Summary of Profit and Loss Statement 58
Balance Sheet 60
Summary of Balance Sheet 60
Cash Flow Statement 62
Summary of Cash Flow Statement 62
Key Financial Ratio Analysis 64
Johnson & Johnson - Ratio Charts 65
Activity Ratio Charts 65
Growth Ratios Charts 66
Leverage Ratio Charts 67
Liquidity Ratio Charts 68
Profitability Ratio Charts 69
Competing Players 70
Snapshot of Competing Players 71
GE HealthCare Technologies, Inc. 71
Key Company Facts 71
Company Description 71
Pfizer Inc. 72
Key Company Facts 72
Company Description 72
Sanofi S.A. 73
Key Company Facts 73
Company Description 73
The Procter & Gamble Company 74
Key Company Facts 74
Company Description 74
Merck & Co., Inc. 75
Key Company Facts 75
Company Description 75
Johnson & Johnson - In the News 76
14-Feb-2025 - Johnson & Johnson to Resume U.S. VARIPULSE Cases 76
13-Feb-2025 - New nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody diseases 77
13-Feb-2025 - Johnson & Johnson Statement on Phase 3 E.mbrace Study 77
03-Feb-2025 - CHMP recommends subcutaneous RYBREVANT (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer 79
21-Jan-2025 - SPRAVATO (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression 81
18-Dec-2024 - Johnson & Johnson submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA (ibrutinib) in adult patients with previously untreated mantle cell lymphoma (MCL) who are eligible for autologous stem cell transplant 83
17-Dec-2024 - Johnson & Johnson Participates in the Inauguration of World Health Organization (WHO) Academy to Improve Training and Education of Health Workers Globally 83
16-Dec-2024 - Johnson & Johnson submits application seeking U.S. FDA approval of SIMPONI (golimumab) for the treatment of pediatric ulcerative colitis 85
12-Dec-2024 - U.S. FDA Expands Indication for Impella Heart Pumps to Treat Pediatric Patients 86
09-Dec-2024 - CARVYKTI (ciltacabtagene autoleucel) demonstrated significantly higher rates of minimal residual disease (MRD) negativity compared to standard therapies in the CARTITUDE-4 study 88
10-Sep-2024 - Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT (amivantamab-vmjw) 90
10-Sep-2024 - Johnson & Johnson Updates the Brand Identity of its MedTech Company Brands 91
08-Sep-2024 - RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer 91
29-Aug-2024 - Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis 94
29-Aug-2024 - DePuy Synthes Launches MatrixSTERNUM Fixation System for Enhanced Chest Stability Following Cardiac Surgery 96
Johnson & Johnson - Key Deals 98
14-Nov-2024 - Johnson & Johnson MedTech Announces Strategic Agreement with Responsive Arthroscopy to Expand Sports Soft Tissue Solutions 98
09-Oct-2024 - Johnson & Johnson Completes Acquisition of V-Wave 99
20-Aug-2024 - Johnson & Johnson to Acquire V-Wave 99
11-Jul-2024 - Johnson & Johnson strengthens pipeline to lead in atopic dermatitis with acquisition of Yellow Jersey Therapeutics 102
05-Apr-2024 - Johnson & Johnson to Acquire Shockwave Medical 102
Appendix 104
Definitions 104
SWOT Analysis 104
PESTLE Analysis 104
Value Chain Analysis 104
ESG Spotlight 104
Financial Deep Dive 104
Financial Ratios - 105
Activity Ratios 105
Growth Ratios 106
Leverage Ratios 107
Liquidity Ratios 108
Market Ratios 109
Profitability Ratios 109
Research Methodology 110
Disclaimer 111
Contact Us 111

Tables
Table 1: Johnson & Johnson - Company Facts
Table 2: Johnson & Johnson - Digital Presence
Table 3: Johnson & Johnson - Top Executives
Table 4: Johnson & Johnson - Top Executives Biographies
Table 5: Johnson & Johnson - Subsidiaries
Table 6: Johnson & Johnson - Key Joint Ventures
Table 7: Johnson & Johnson - Products
Table 8: Johnson & Johnson - Historic Events
Table 9: Johnson & Johnson - Share Price Trend - Feb-2024 to Feb-2025
Table 10: Johnson & Johnson - Ratio Analysis - 2021-2023
Table 11: Johnson & Johnson - Competing Players
Table 12: Competing Players - GE HealthCare Technologies, Inc. - Key Company Facts
Table 13: Competing Players - Pfizer Inc. - Key Company Facts
Table 14: Competing Players - Sanofi S.A. - Key Company Facts
Table 15: Competing Players - The Procter & Gamble Company - Key Company Facts
Table 16: Competing Players - Merck & Co., Inc. - Key Company Facts

Charts
Figure 1: Johnson & Johnson- SWOT Analysis
Figure 2: Johnson & Johnson - PESTLE Analysis
Figure 3: Johnson & Johnson - Average Share Price Trend - Feb-2024 to Feb-2025
Figure 4: Johnson & Johnson - Profit and Loss Statement - 2022-2024
Figure 5: Johnson & Johnson - Balance Sheet - 2022-2024
Figure 6: Johnson & Johnson - Cash Flow Statement 2022-2024
Figure 7: Johnson & Johnson - Activity Ratio Charts
Figure 8: Johnson & Johnson - Growth Ratio Charts (Value %)
Figure 9: Johnson & Johnson - Leverage Ratio Charts
Figure 10: Johnson & Johnson - Liquidity Ratio Charts
Figure 11: Johnson & Johnson - Profitability Ratio Charts (Value %)

  • Not Sure / Need Reassuring
    • Confirm Content
      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages
      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives
      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices
      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts
      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies
      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses
      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License
      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats
      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery
      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges
      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card
      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer
      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security
      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security
      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE